Family Management Corp increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 87.1% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 24,202 shares of the biopharmaceutical company’s stock after purchasing an additional 11,270 shares during the period. Family Management Corp’s holdings in Pfizer were worth $1,048,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of the stock. Evolution Wealth Advisors LLC bought a new stake in shares of Pfizer during the second quarter worth approximately $34,000. IMA Wealth Inc. boosted its holdings in shares of Pfizer by 144.5% during the second quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 477 shares during the period. Winch Advisory Services LLC boosted its holdings in shares of Pfizer by 69.6% during the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 336 shares during the period. Financial Gravity Wealth Inc. boosted its stake in shares of Pfizer by 33.2% in the second quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 257 shares during the period. Finally, Karp Capital Management Corp bought a new stake in shares of Pfizer in the fourth quarter valued at approximately $53,000. Institutional investors and hedge funds own 71.68% of the company’s stock.
NYSE PFE traded up $0.57 on Friday, hitting $37.08. 10,271,752 shares of the company’s stock traded hands, compared to its average volume of 19,822,398. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 1-year low of $33.97 and a 1-year high of $46.47. The firm’s 50-day moving average price is $36.04 and its two-hundred day moving average price is $40.59. The firm has a market capitalization of $201.88 billion, a PE ratio of 12.36, a P/E/G ratio of 2.90 and a beta of 0.65.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd were issued a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.88%. The ex-dividend date was Thursday, August 1st. Pfizer’s payout ratio is 48.00%.
Several equities research analysts recently issued reports on the company. Morgan Stanley cut their price target on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 27th. UBS Group reiterated a “neutral” rating and issued a $43.00 price target on shares of Pfizer in a research note on Monday, August 5th. JPMorgan Chase & Co. boosted their price target on Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday. They noted that the move was a valuation call. Credit Suisse Group reiterated a “neutral” rating on shares of Pfizer in a research note on Monday, August 12th. Finally, Bank of America cut Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 30th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and a consensus target price of $45.88.
In other news, Director Scott Gottlieb purchased 3,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were purchased at an average price of $34.72 per share, with a total value of $104,160.00. Following the transaction, the director now owns 3,000 shares in the company, valued at approximately $104,160. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Pfizer Inc purchased 50,000 shares of the stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is owned by corporate insiders.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: Special Dividends
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.